AM-Pharma B.V., a Bunnik, Netherlands-based clinical stage biopharmaceutical company focused on a treatment for acute kidney injury (AKI), raised €116m [$133m] in funding.
The round was co-led by new investors LSP and Andera Partners, and includes founding investor Forbion together with other existing investors, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare.
These new funds will be used to carry out a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated acute kidney injury (SA-AKI).
Founded in 2001 and led by Erik van den Berg, CEO, AM‐Pharma develops a treatment for acute kidney injury (AKI) with innovative recombinant human Alkaline Phosphatase therapeutic (recAP). The company reported positive results from a Phase II study of recAP in patients with sepsis associated AKI (SA-AKI) and is preparing to initiate a pivotal Phase III trial of recAP in patients with SA-AKI.
AM-Pharma, which has raised over €195m in equity and debt to date, is also exploring the development of recAP for other indications including ulcerative colitis (UC), necrotizing enterocolitis (NEC) and hypophosphatasia (HPP).
AM-Pharma’s Board of Directors will consist of Martijn Kleijwegt and Felice Verduyn van Weegen from LSP, Raphael Wisniewski from Andera, Remi Droller from Kurma and Geert-Jan Mulder from Forbion.